Podcasts about health quality

Elissa is joined by her friend, Bill Malloy, who was among the founders of St. Anthony's Orthodox Church in Spring, Texas. He loves to do volunteer work—at Texas Children's Hospital for years, and now at Institute for Health Quality and Ethics in Santa Fe.

Cherish Your Health is celebrating the launch of its new revamped website. They believe it will be a successful website because they are planning intensive SEO. A small party with the people who created the new service. Further information can be found at https://www.cherishyourhealth.com/ Cherish Your Health City: Woodland Address: 1649 College Street Website: http://www.cherishyourhealth.com

Alison Cammack, PhD, MPH, lead author and health scientist on the CDC suicide prevention team, provides an overview of the CDC's new Vital Signs report, with new data on suicide rates and variables; Stacy Scott, PhD, National Institute for Children's Health Quality, discusses the role of public health in the effort to reduce infant mortality; an ASTHO blog article looks at better protecting children's health through emergency preparedness.  CDC: Vital Signs: Suicide Rates and Selected County-Level Factors - United States, 2022 NICHQ: Infant Mortality CoIIN Prevention Toolkit NICHQ: National Infant Mortality Awareness Month Toolkit ASTHO: How Emergency Preparedness Can Better Protect Children's Health  

In this episode, Eileen interviews Meg Hayden, a real estate broker and single mom. They discuss the importance of being intentional in all aspects of life, including relationships, health, and finances. Meg shares her experiences with real estate development and the importance of building a strong team. She also talks about her movement, the Sisterhood Swap, which aims to provide clothing and support to those in need. Meg offers two online courses, The Landlady and Financial Femme, to help educate and empower others. Overall, the conversation emphasizes the power of intention and community. Click here to follow Meg on IG : https://www.instagram.com/meghaydenrealtor/ DM meg directly to find out more about her courses! Thank you for listening. If you've enjoyed this episode leave a 5 star review, share this episode with a friend and download to never miss a show! Come workout with US! Join our FREE 8 week workout Challenge. You'll gain access to meal and snack ideas, relatable and honest support, a community of parents who are trying to do all the life things AND get in shape, giveaways, discounts and links to our favorite supplements, clothing, at home gym equipment and everyday house hold products that just make life a little easier! Click the link below to get all the goods! https://systeme.io/funnel/share/3973656ea73814c1460cc8c8177cbdcd9dc8856

Ever heard that abortion is necessary to save a woman's life? Think again!    In a recent episode of Trending with Timmerie, Dr. Ingrid Skop, an obstetrician and the Vice President of Medical Affairs for the Charlotte Lozier Institute, joins Timmerie to tackle one of the most persistent pro-abortion myths: the idea that abortion is necessary to save the life of a mother. Dr. Skop, who has delivered over 5,000 babies, asserts that abortion is never medically necessary to save a mother's life. Instead, the focus should be on early delivery if complications arise, ensuring both mother and child receive the care they need.   Key Points from the Podcast:    Medical Misinformation & Misleading Practices:   Since the 1960s and 70s, Timmerie explains that the medical community has often misinformed women about their fertility and health, pushing birth control and abortion as solutions to underlying health issues.   Abortion & Emergency Medical Treatment:   Dr. Skop clarifies that in emergency situations, the appropriate medical response is to stabilize the mother and deliver the baby, not perform an abortion.   EMTALA (Emergency Medical Treatment and Labor Act of 1986) requires hospitals to provide emergency care, which includes evaluating and stabilizing both the mother and unborn child.   Supreme Court & Legal Battles:   The Biden administration's attempts to use EMTALA to promote abortion conflicts with state laws. However, Dr. Skop is optimistic that the Supreme Court will uphold the states' rights to protect both mother and child in emergencies.   Misleading Pro-Abortion Arguments:   Pro-abortion advocates often use the argument of "life of the mother" to justify abortion, despite it not being necessary. Most medical emergencies occur later in pregnancy when early delivery is viable.   Pro-Life Laws & Women's Health:   Quality medical practice involves early delivery, not abortion. Abortion, especially later in pregnancy, is riskier for women and often coerced by external pressures.   The Charlotte Lozier Institute provides scientific, peer-reviewed data debunking pro-abortion claims and supporting pro-life laws.   Global Perspective:   The U.S. is one of only eight countries that allows elective abortions throughout the entire pregnancy, a practice that is both inhumane and unnecessary. This is a heartbreaking reality that our nation needs to correct, and we need to turn back to the Lord.    Dr. Skop emphasizes that abortion till birth is a tragic reality in the U.S., often justified under vague definitions of health that include social and financial reasons. This misrepresentation leads to coercive practices that harm women and their babies. These women truly want to keep their children. Can you only imagine the pain and pressure they feel? We need to show them compassion and better choices, and walk with them through this hurt.    Pro-Life, Pro-Woman:    "Pro-life is pro-woman."   Pro-life laws protect women and children. The reality is, women facing crises during pregnancy need comprehensive care, not abortion. Educate yourself and others using resources from the Charlotte Lozier Institute, where science and compassion meet to support life at all stages. Here's one of Dr. Skop's publications.    Let's spread the truth and support the sanctity of life!   The best way to listen to the Best of the Week is on our #1 Free Catholic App. It's free, and always will be! To get and share the Relevant Radio app, check it out here.

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss promising combination therapies and other compelling advances in genitourinary cancers in advance of the 2024 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I'm the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News. I'm delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of genitourinary cancers at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that will be featured at the 2024 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode. Jeanny, it's great to have you on the podcast. Dr. Jeanny Aragon-Ching: Thank you so much, Dr. Agarwal. It's a pleasure to be here. Dr. Neeraj Agarwal: So, Jeanny, let's start with some bladder cancer abstracts. Could you tell us about the Abstract 4509 titled, “Characterization of Complete Responders to Nivolumab plus Gemcitabine Cisplatin versus Gemcitabine Cisplatin Alone in Patients with Lymph Node Only Metastatic Urothelial Carcinoma from the CheckMate 901 Trial.”  Dr. Jeanny Aragon-Ching: Of course, Neeraj, I would be delighted to. First, I would like to remind our listeners that the CheckMate 901 trial was a randomized, open-label, phase 3 study, in which this particular sub-study looked at cisplatin-eligible patients with previously untreated, unresectable, or metastatic urothelial carcinoma who were assigned to receive the combination of gemcitabine and cisplatin, followed by up to 2 years of nivolumab or placebo. Based on the data presented at ESMO 2023 and subsequently published in the New England Journal of Medicine, which shows significantly improved progression-free survival and overall survival in patients receiving the combination of gemcitabine, cisplatin, and nivolumab, this regimen was approved in March 2024 as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma.  In the abstract that will be featured at ASCO this year, Dr. Matt Galsky and colleagues present a post-hoc analysis that aims to characterize a subset of patients with complete response as well as those with lymph node-only metastatic disease. In patients receiving the experimental treatment, 21.7% achieved a complete response, while 11.8% of the patients in the control arm achieved a complete response.  Among these complete responders, around 52% had lymph- node-only disease in both arms. Furthermore, when characterizing the subgroup of patients with lymph-node-only disease, those receiving the combination of gemcitabine-cisplatin plus nivolumab had a 62% reduction in the risk of progression or death and a 42% reduction in the risk of death compared to those treated with gemcitabine-cisplatin alone.  The median overall survival in the experimental arm in this subgroup was around 46.3 months, while it was only 24.9 months in the control arm. The ORR in patients with lymph-node-only disease receiving gem-cis plus nivo was about 81.5% compared to 64.3% in those treated with gem-cis alone. Dr. Neeraj Agarwal: Thank you, Jeanny, for the excellent summary of this abstract. We can say that nivolumab plus gemcitabine-cisplatin induced durable disease control and clinically meaningful improvements in OS and PFS compared to gem-cis alone in patients with lymph- node-only metastasis, and deserves to be considered as one of the options for these patients.  In a similar first-line metastatic urothelial carcinoma setting, Abstract 4502, also reported data on a recently approved combination of enfortumab vedotin and pembrolizumab. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, as quick reminder to our audience, this regimen was tested in the EV-302 phase 3 trial, where patients with previously untreated, locally advanced or metastatic urothelial carcinoma were randomized to receive enfortumab vedotin, plus pembrolizumab or gemcitabine plus either cisplatin or carboplatin. These data were also first presented at ESMO 2023 and subsequently published in the New England Journal of Medicine. They showed that this immune based combination significantly improved both progression free survival and overall survival, which were the primary endpoints compared to chemotherapy. In this abstract, Dr. Shilpa Gupta from the Cleveland Clinic and colleagues present the results of patient reported outcomes based on quality-of-life questionnaires in this trial.  Time to pain progression and time to confirm deterioration were numerically longer in patients treated with EV plus pembro, and patients with moderate to severe pain at baseline receiving this combination had a meaningful improvement in the Brief Pain Inventory Short-Form worst pain from week 3 through 26. Dr. Neeraj Agarwal: Thank you, Jeanny. This means that patients treated with EV plus pembro did not only have improved survival compared with platinum-based chemotherapy, but also improvement in their quality-of-life and functioning, further supporting the value of this combination for patients with locally advanced or metastatic urothelial carcinoma. This is terrific news for all of our patients.   Before we wrap up the bladder cancer section, would you like to tell our listeners about Abstract 4565, which provides the data on the efficacy of trastuzumab deruxtecan in patients with bladder cancer? Dr. Jeanny Aragon-Ching: Yes, Neeraj; this is timely given the recent FDA approval, which we will talk about. The abstract is titled, “Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2 Expressing Solid Tumors: Results from the Bladder Cohort of the DESTINY-PanTumor02 Study.” And as a quick reminder, the DESTINY-PanTumor02 was a phase 2 open-label study where trastuzumab deruxtecan, an antibody-drug conjugate targeting HER2 expression on cancer cells, was evaluated in patients with HER2-expressing locally advanced or metastatic disease who previously received systemic treatment or who had no other treatment options. The expression of HER2 was evaluated on immunohistochemistry by local or central testing.   The primary endpoint was confirmed objective response rate by investigator assessment. Secondary endpoints included duration of response, progression free survival, disease control rate, and safety. The primary analysis, which was published in the Journal of Clinical Oncology, showed an ORR of 37.1% and responses across all cohorts and the median duration of response was 11.3 months. Based on these results, fam-trastuzumab deruxtecan-nxki was just granted accelerated FDA approval for unresectable or metastatic HER2-positive solid tumors in April 2024.  So, back to this abstract; Dr. Wysocki and colleagues report the results of the bladder cancer cohort. This study included 41 patients with urothelial cancer and at a median follow up of around 12.6 months, the objective response rate among these patients was 39%, the median PFS was 7 months, and the duration of response median was 8.7 months. The disease control rate at 12 weeks was around 71%. Regarding the safety profile, 41.5% of patients experienced grade ≥3 drug related adverse events and interstitial lung disease or pneumonitis did occur in about 4 patients. Although there was no statistical comparison between different groups, the ORR was numerically highest among the HER2 3+ group with 56.3%.  Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data support consideration of trastuzumab deruxtecan as a salvage therapy option for pre-treated patients with HER2 expressing urothelial cancers and show that we are extending our treatment options to include therapies with novel mechanisms of action. This is definitely exciting news for patients with bladder cancer. Dr. Jeanny Aragon-Ching: Yes, absolutely, Neeraj. Now, let's switch gears a bit to prostate cancer. Could you tell us about Abstract 5005 which is titled, “EMBARK Post Hoc Analysis of Impact of Treatment Suspension on Health Quality-of-Life?” Dr. Neeraj Agarwal: Of course, I'd be happy to. So, enzalutamide was recently granted FDA approval for the treatment of patients with non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high-risk of metastasis, based on the results of the EMBARK trial, which was a phase 3 study where patients with high-risk biochemical recurrence were randomized to receive either enzalutamide with leuprolide, enzalutamide monotherapy, or placebo plus leuprolide. The primary endpoint was metastasis-free survival with secondary endpoints including overall survival and safety.  Results showed that patients receiving enzalutamide alone or enzalutamide plus leuprolide had significantly improved metastasis-free survival compared to those treated with leuprolide alone while preserving health-related quality-of-life.   One important aspect in the design of the trial was that patients who achieved undetectable PSA at week 37 underwent treatment suspension. The treatment was resumed if PSA rose to more than 2 ng/ml for patients who underwent radical proctectomy or when PSA rose to more than 5 ng/ml for those who did not undergo surgery.  In this abstract, Dr. Stephen Freedland and colleagues present a post-hoc analysis of health-related quality-of-life outcomes after treatment suspension between weeks 37 and 205. They found that treatment was suspended in 90.9% of patients receiving enzalutamide plus leuprolide, 85.9% of those receiving enzalutamide monotherapy, and 67.8% of those receiving leuprolide monotherapy. Among those patients who stayed on treatment suspension, a trend toward numerical improvement in health-related quality-of-life after week 37 was seen in all 3 arms and this reached clinically meaningful threshold at week 205 in pain questionnaires, physical well-being, urinary and bowel symptoms. For hormonal treatment side effects, all arms reached clinically meaningful improvement at the subsequent assessments of week 49 to week 97. However, patients slowly deteriorated, with clinically meaningful deterioration at week 205 relative to week 37 in patients receiving the combination of enzalutamide and leuprolide and those treated with leuprolide.    Concerning sexual activity, a clinically meaningful improvement was reported only in patients receiving enzalutamide plus leuprolide, possibly because sexual function was better preserved prior to suspension in the enzalutamide monotherapy arm and thus there was less opportunity for “improvement” while on suspension.  Dr. Jeanny Aragon-Ching: Thank you, Neeraj, for this great summary. This analysis confirms that treatment suspension in good responders might lead to a clinically meaningful improvements in health-related quality-of-life.   Now, moving on to patients with metastatic castration-resistant prostate cancer, what can you tell us, about Abstract 5008 titled, “Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore”?  Dr. Neeraj Agarwal: Sure, Jeanny. The PSMAfore trial was a phase 3 study that compared the efficacy of 177Lu-PSMA-617 versus an ARPI switch in patients with mCRPC and prior progression on a first ARPI, and not previously exposed to docetaxel chemotherapy. The primary endpoint was rPFS and OS was an important secondary endpoint. The primary analysis presented at ESMO 2023 showed a significantly prolonged rPFS in patients receiving lutetium. In the abstract that will be featured at the 2024 ASCO Annual Meeting, Dr. Johann De Bono and colleagues present an exploratory analysis regarding the associations between baseline circulating tumor DNA and outcomes.  ctDNA fraction was evaluated in all samples as well as alterations in key prostate cancer drivers prevalent in more than 10% of participants.  The investigators sought to interrogate the association of ctDNA fraction or alterations with rPFS, PSA response, and RECIST response at data cutoff. They showed that median rPFS was significantly shorter in patients with a ctDNA fraction >1% compared to those with a fraction < 1% regardless of the treatment arm. Furthermore, ctDNA fraction >1% was also associated with worst RECIST response and PSA50 response. Regarding prostate cancer drivers, median rPFS was significantly shorter in patients with alterations in the AR, TP53 or PTEN in both treatment arms. There was no significant association between ctDNA alterations and PSA or objective responses. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. So, these results show that the presence of a ctDNA fraction >1% or alterations in AR, P53 and PTEN were all associated with worse outcomes regardless of treatment with lutetium or change in the ARPI. These data are definitely important for counseling and prognostication of patients in the clinic and may guide the design of future clinical trials. Let's move on to kidney cancer. Neeraj, do you have any updates for us?  Dr. Neeraj Agarwal:  Sure. In Abstract 4512 titled, “A Multi-institution Analysis of Outcomes with First-Line Therapy for 99 Patients with Metastatic Chromophobe Renal Cell Carcinoma,” Dr. Sahil Doshi and colleagues present a retrospective, multi-institutional study comparing survival outcomes, including time-to-treatment failure and overall survival, between different first-line treatment options in patients with metastatic chromophobe renal cell carcinoma, where limited clinical trial data exists to guide systemic therapy. They categorized patients into 4 treatment groups: and immune checkpoint inhibitors + targeted therapy doublets (such as ICI VEGF TKI); pure immune checkpoint inhibitor monotherapy and doublets (such as ipilimumab plus nivolumab); targeted therapy doublets (such as lenvatinib plus everolimus), and targeted monotherapy (such as sunitinib).  They identified 99 patients, of whom 54 patients received targeted monotherapy, 17 received ICI VEGF-TKI, 14 received targeted doublet, and 14 patients received only ICI therapies. So the patients treated with any doublet containing a targeted agent had a 52% decrease in the risk of treatment failure and a 44% decrease in the risk of death compared to those treated with targeted monotherapy. The median time to treatment failure was 15 months with IO-targeted doublet, and the median overall survival was 56 months. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. So, these results show that targeted doublet regimens resulted in a longer time to treatment failure and overall survival compared to any monotherapy in patients with chromophobe metastatic RCC and definitely provides valuable insights on treatment selection, albeit I would say there's still a small number of patients that were included in this retrospective analysis. Dr. Neeraj Agarwal: I completely agree this is a relatively small number of patients, but I decided to highlight the abstract given how rare the cancer is, and it is highly unlikely that we'll see large randomized clinical trials in patients with metastatic chromophobe renal cell carcinoma.  So, before we wrap up the podcast, what would you like to tell us about Abstract 5009 which is titled, “A Phase II Trial of Pembrolizumab Platinum Based Chemotherapy as First Line Systemic Therapy in Advanced Penile Cancer: HERCULES (LACOG 0218) Trial.” Dr. Jeanny Aragon-Ching: I'm glad you brought this up, Neeraj. As our listeners may know, advanced penile squamous cell carcinoma has a poor prognosis with limited treatment options. From this perspective, the results of the LACOG 0218 trial are very important. As you mentioned, this was a phase 2 single-arm study evaluating the addition of pembrolizumab to platinum-based chemotherapy as first-line treatment in patients with metastatic or locally advanced penile squamous cell carcinoma not amenable to curative therapy. Patients enrolled received chemotherapy, namely 5-Fluorouracil with cisplatin or carboplatin and pembrolizumab 200 mg IV every 3 weeks for 6 cycles, followed by pembrolizumab 200 mg IV every 3 weeks up to 34 cycles. The primary endpoint was confirmed overall response rate by investigator assessment.  In the 33 patients eligible for the efficacy analysis, the confirmed ORR by investigator assessment was 39.4% and included one complete response and 12 partial responses. The confirmed ORR was 75% in patients with high TMB and 55.6% in patients positive for HPV16, making TMB and HPV16 potential predictive biomarkers for efficacy in this study. Concerning the toxicity profile, any grade treatment-related adverse events were reported in around 92% of patients, and grade 3 or more treatment-related adverse events occurred in 51% of patients. 10.8% of patients discontinued treatment due to adverse events.  Dr. Neeraj Agarwal: Thank you, Jeanny. I would like to add that HERCULES is the first trial to demonstrate the efficacy of an immune checkpoint inhibitor in advanced penile squamous cell carcinoma with a manageable safety profile. Thus, the combination of ICI with platinum-based chemotherapy is a promising treatment for advanced penile squamous cell carcinoma and warrants further investigation.  Dr. Jeanny Aragon-Ching: I agree, Neeraj. Any final remarks before we conclude today's podcast? Dr. Neeraj Agarwal: Jeanny, I really want to thank you for your participation and valuable insights. Your contributions are always appreciated, and I sincerely thank you for taking the time to join us today. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. It was a pleasure.  Dr. Neeraj Agarwal:  As we bring this podcast to an end, I would like to acknowledge the significant advances happening in the treatment of patients with genitourinary cancers. During our upcoming 2024 ASCO Annual Meeting, there will be an array of different studies featuring practice-changing data presented by researchers and physicians from around the globe. I urge our listeners to not only participate in this event to celebrate these achievements, but to also play a role in sharing these cutting-edge data with healthcare professionals worldwide. Through our collective efforts, we can surely optimize the benefits of patients on a global scale.   And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast. Thank you very much.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:  Dr. Neeraj Agarwal  @neerajaiims  Dr. Jeanny Aragon-Ching    Follow ASCO on social media:   @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn       Disclosures:    Dr. Neeraj Agarwal:     Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences    Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas     Dr. Jeanny Aragon-Ching:  Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono  Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,   Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics. 

The Michigan Department of Health and Human Services will fund hospital birthing units that participate in two community programs. Plus, Pensole Lewis College – Michigan's only Historically Black College, and the only one focused on design – is working with the NFL to showcase the work of local artists during this week's draft events. Do you have a community story we should tell? Let us know in an email at detroiteveningreport@wdet.org.

Michael Rubino is championing “the new frontier of holistic health.” He is an air quality expert and wellness advocate who is bridging the gap between our homes and their direct impact on health.  He is the founder of HomeCleanse, a company dedicated to addressing the worldwide health epidemic caused by poor indoor air quality. He works closely with the company's advisory team, which includes global well-being trailblazers Deepak Chopra's The Chopra Foundation and Gwyneth Paltrow, to achieve the company's mission to improve the quality of life for 100 million people each year by 2030. Rubino is also the founder of Change the Air Foundation, a nonprofit committed to empowering the world to achieve better health by establishing safer and healthier indoor environments.  In an effort to share his expert knowledge, Rubino is an ongoing contributor to MindBodyGreen. He has been featured on Gwyneth Paltrow's The goop Podcast, Vice TV, Vogue, LiveStrong, Dr. Will Cole's The Art of Being Well Podcast, Forbes, MarketWatch, and USA Today. Rubino has appeared on television as a featured expert, including local NBC, Fox, and ABC affiliates, to name a few.

Your bladder plays a huge role in labor! If it is full, it is taking up valuable space that baby needs to continue their descent down and out. You should be emptying your bladder frequently during labor—and that's exactly what this episode is about! HeHe is diving into the why and when behind peeing often in labor.   A 2017 study stated that postpartum hemorrhage occurs in 3% of births, but the CDC Foundation suggests that up to 70% of those may be avoidable. It's been shared time and time again that having a full bladder can increase the risk of postpartum hemorrhage and this episode is going to spill the beans on what you need to know!   Join The Birth Lounge: https://www.thebirthlounge.com/   Episode Resources: 2017 study: https://pubmed.ncbi.nlm.nih.gov/28502... CDC Foundation: https://www.cdcfoundation.org/sites/default/files/files/ReportfromNineMMRCs.pdf National Insitute for Children's Health Quality: https://nichq.org/insight/taking-leading-cause-maternal-death-improving-postpartum-hemorrhage-care EBB: https://evidencebasedbirth.com/evidence-on-pitocin-during-the-third-stage-of-labor/ Maternal Mortality Review Information App: https://reviewtoaction.org/implement/getting-started ACOG: https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2017/10/postpartum-hemorrhage ACOG Expansion: https://www.acog.org/news/news-releases/2017/09/acog-expands-recommendations-to-treat-postpartum-hemorrhage

This episode features Dr. Erkeda DeRouen, Digital Health Quality Consultant on Health Tech & Health Equity. Here, she discusses her background, her podcast “The Prospective Doctor” & upcoming book, what trends in healthtech that she is excited about, and much more!

In this episode I look at the true essence of health.We live a world that is increasingly confusing in terms of health messaging and priorities given the amount of inequality in the world.I take a look at some basics of what is important to us in our lives which people may not consider important for health but not only nourish us as humans but are important to both our short and long term health.Links:Self-esteem and the brain: https://www.ucl.ac.uk/news/2017/oct/self-esteem-mapped-human-brainHugs (they really are good for us): https://www.healthline.com/health/hugging-benefitsQuality of Life scoring: https://positivepsychology.com/quality-of-life-questionnaires-assessmentsWeightless by Marconi Union (the most relaxing tune in the world?): https://www.google.com/search?client=safari&rls=en&q=weightless+by+marconi+union&ie=UTF-8&oe=UTF-8Social connectedness (what we know): https://www.cdc.gov/emotional-wellbeing/social-connectedness/affect-health.htmEating together (like my taxi driver): https://blog.swedish.org/swedish-blog/7-benefits-of-eating-together-as-a-familySalutogenesis: https://www.local.gov.uk/case-studies/salutogenesis-introductionCome and say Hi to me in London: https://www.eventbrite.co.uk/e/dr-ayan-panja-the-health-fix-tickets-753931006937Pre-order THE HEALTH FIX paperback version now (thank you for your support): https://www.amazon.co.uk/Health-Fix-Dr-Ayan-Panja/dp/1914239326/ref=monarch_sidesheet Hosted on Acast. See acast.com/privacy for more information.

This episode introduces a Swiss research paper titled "Cross-Sectional Validity and Specificity of Comprehensive Measurement in Lower Extremity Lymphedema and Lipedema: A Comparison of Five Outcome Assessment Tools."This peer-reviewed paper was published in the Health Quality and Life Outcomes journal in July 2020. The study's primary goal was to assess the effectiveness of five different assessment instruments in evaluating the outcomes of lymphedema and lipedema treatments.The authors aimed to determine the instruments' validity in measuring various aspects and health dimensions of these conditions while also assessing their ability to differentiate between lymphedema and lipedema.This research is particularly valuable for healthcare providers treating women with lipedema, as it provides insights into reliable assessment tools they can consider for their practice.

Ashlei Spivey, Executive Director at IBeBlackGirl, and Stacey Penny, Senior Project Director at the National Institute for Children's Health Quality, join us to discuss the key challenges black mothers face while pregnant and birthing. They share the work they are each doing to help improve health outcomes for black birthing people and women of color as well as some of the programs and initiatives that have been implemented to bring more awareness to and address the maternal health crisis in America.  The show features a number of programs and initiatives that can support a health system's efforts to reduce maternal morbidity and mortality. Our show notes are available at www.centerhealthequity.com with references to the many programs mentioned in our conversation.

This week we have the honor of being joined by a world-renowned family physician and health equity expert, with deep experience in value-based care transformation, technology and innovation, and health disparities improvement.  You are going to hear from the one and only Dr. Nwando Olayiwola, a leader in this Race to Value who is committed to ensuring that everyone has access to fair, high quality and equitable health and health care, no matter their background. To achieve this, she has committed her career to health system reform, practice transformation, primary care redesign and leveraging technology and other innovations to mitigate health disparities. Dr. Olayiwola is Nigerian American physician, professor, author, speaker, consultant, and health equity leader. She was named the American Telemedicine Associate's Woman of the Year in 2019, she was named one of the most influential minority executives in healthcare by Fierce Healthcare in 2021. Dr. O is a tireless advocate for healthcare of underserved populations, women and girls, and community and social determinants of health and innovations in technology, and the intersection of social justice and healthcare. As the inaugural Chief Health Equity Officer and senior VP of Humana, a role that she started in 2021, and she's responsible for setting equity agenda and strategy for Humana. In this episode, you will learn about the enablement of an equitable healthcare ecosystem through actionable data, performance measurement and quality improvement, health equity innovation, and relationship-based care. Episode Bookmarks:  01:30 Introduction to Dr. J. Nwando Olayiwola, a Nigerian American physician, professor, author, speaker, consultant, and health equity leader. 02:30 Dr. O is the inaugural Chief Health Equity Officer and senior VP of Humana. 04:00 Personal background and formative experiences that has led Dr. O towards a career path in healthcare equity transformation. 05:30 The Health Equity Journey at Humana. (“Making Health Equity Part of the Value of Value-Based Care”) 06:45 Humana became a pioneer of health justice and health equity in rebuilding and uniting Louisville after the murder of Breonna Taylor. 07:00 Humana's Bold Goal Population Health Initiative to enable an equitable healthcare ecosystem. 07:45 “We need to innovate constantly in the way that we deliver and finance healthcare. It must fit within the lives of people's own lived experience.” 08:00 Optimism for the evolution of our healthcare ecosystem to better prioritize health equity. 09:00 “We must do everything we can to eliminate barriers to healthcare that are unnecessary, that are avoidable, and that are unjust.” 09:45 Imagining a world where healthcare is more than just having an insurance card – it actually becomes an equitable ecosystem of liberation and authenticity. 10:30 Dr. O provides specifics on the various types of health disparities that we encounter in our country and how those impact minoritized and marginalized populations. 12:00 Dr. O's TED Talk: “Combating Racism and Place-ism in Medicine” 13:00 How is Humana positioning itself as a catalyst for equity innovation by leveraging it health plan and provider assets collectively? 15:00 How the Health Equity movement mirrors the path of the Health Quality movement following the “To Err is Human” report. 16:30 Referencing landmark National Academy of Medicine paper: “An Equity Agenda for the Field of Health Care Quality Improvement” 17:00 Measuring health equity on dashboards measuring organizational performance. 18:00 “We must get the right data to validate we are providing culturally affirming, culturally sensitive, and culturally humble care to people we're caring for.” 18:00 Referencing NEJM Catalyst article on how Humana developed a health disparities impact measure:  “Building the Foundation for Reducing Disparities in Medicare Advantage” 19:30 The need for committed leadership to support health equity work.

Dr. Jinks interviews NAFCC President and CEO Nicole Lamoureax and Greenville Free Medical Clinic President and CEO Suzie Foley about their leadership of the Roadmap to Health Equity (RHE). The RHE is a national metrics initiative designed to lift the quality, equity, and impact of over 1,400 free and charitable clinics across the United States.

Dr. Carl Horsley is an Intensive Care specialist at Middlemore Hospital in Auckland, having previously completed training in Emergency Medicine. He also is the Clinical Lead for System Safety at the Health Quality & Safety Commission, with a focus on understanding the way in which the wider healthcare system shapes the conditions in which care is provided.He has recently completed an MSc in Human Factors and System Safety at Lund University, Sweden and is part of the Resilient Healthcare Society, an international collaboration of researchers, clinicians and safety scientists. His current focus is on how to bring together Te Ao Māori and modern safety science to create a system that supports good care at all levels.In this episode, we discuss his shift from training in emergency medicine to intensive care, his work in human factors and system safety and what the practical implementation of this looks like, creating psychologically safe workplaces, the three phases experienced by doctors when causing harm/adverse events, and advice for prospective ICU applicants. Support the showAs always, if you have any feedback or queries, or if you would like to get in touch with the speaker, feel free to get in touch at doctornos@pm.me. Audio credit:Bliss by Luke Bergs https://soundcloud.com/bergscloudCreative Commons — Attribution-ShareAlike 3.0 Unported — CC BY-SA 3.0Free Download / Stream: https://bit.ly/33DJFs9Music promoted by Audio Library https://youtu.be/e9aXhBQDT9Y

In this episode, I speak with Dr. Mindy Pelz, D.C. is a bestselling author, keynote speaker, nutrition and functional health expert who has spent over two decades helping thousands of people successfully reclaim their health. She is a recognized leader in the alternative health field and a pioneer in the fasting movement, teaching the principles of a fasting lifestyle, diet variation, detox, hormones, and more. Her popular YouTube channel (which just celebrated 24 million lifetime views) regularly updates followers on the latest science-backed tools and techniques to help them reset their health. She hosts one of the leading science podcasts, The Resetter Podcast, and is the author of three best-selling books. Her celebrity clients include Danica Patrick, Leann Rimes, Kat Graham, and influencer Jesse Itzler. Dr. Mindy has appeared on national TV shows including “Extra TV” and “The Doctors,” and has been featured in Well + Good, Parade, Muscle & Fitness, Healthline, and more. Topics Discussed: Fasting is More Than Just Food Impact of Fasting for Women Women's Health Undertand Your Hormones Details Matter Understand the Why Awareness Drives Context Fasting Movement Father & Daughter Relationships Tracking Cycles Help Relationships Practical Guide to Health Instagram: @dr.mindypelz Website: https://drmindypelz.com/ **NEW BOOK: Fast Like a Girl by Dr. Mindy Pelz Reading: Woman (book on Hormones) Listening To: David Sinclair, The Model Health Show, others R&R: HBOT & Walking SUBSCRIBE, SHARE, RATE and REVIEW *Anything discussed in this episode is not medical advice and you should always check with a health professional prior to taking any actions.

In this episode, I speak with Dr. Mindy Pelz, D.C. is a bestselling author, keynote speaker, nutrition and functional health expert who has spent over two decades helping thousands of people successfully reclaim their health. She is a recognized leader in the alternative health field and a pioneer in the fasting movement, teaching the principles of a fasting lifestyle, diet variation, detox, hormones, and more. Her popular YouTube channel (which just celebrated 24 million lifetime views) regularly updates followers on the latest science-backed tools and techniques to help them reset their health. She hosts one of the leading science podcasts, The Resetter Podcast, and is the author of three best-selling books. Her celebrity clients include Danica Patrick, Leann Rimes, Kat Graham, and influencer Jesse Itzler. Dr. Mindy has appeared on national TV shows including “Extra TV” and “The Doctors,” and has been featured in Well + Good, Parade, Muscle & Fitness, Healthline, and more. Topics Discussed: Fasting is More Than Just Food Impact of Fasting for Women Women's Health Undertand Your Hormones Details Matter Understand the Why Awareness Drives Context Fasting Movement Father & Daughter Relationships Tracking Cycles Help Relationships Practical Guide to Health Instagram: @dr.mindypelz Website: https://drmindypelz.com/ **NEW BOOK: Fast Like a Girl by Dr. Mindy Pelz Reading: Woman (book on Hormones) Listening To: David Sinclair, The Model Health Show, others R&R: HBOT & Walking SUBSCRIBE, SHARE, RATE and REVIEW *Anything discussed in this episode is not medical advice and you should always check with a health professional prior to taking any actions.

The aim of this dissertation is to address notable gaps in the literature on social prescribing, namely the lack of an agreed definition of social prescribing and the lack of evidence around social prescribing for children and youth. For upcoming interviews check out the Grad Chap webpage on Queen’s University School of Graduate Studies website […]

A new food study and rating scale is receiving a lot of attention for suggesting that ice cream with nuts or chocolate and potato chips might actually be healthier than a multigrain bagel with raisins. In the study, researchers at Tufts University developed a “food compass,” rating foods on a scale of 1 to 100. […] The post 265. A new scale ranks foods in terms of health quality appeared first on Dr. David Geier - Feel and Perform Better Than Ever.

In this episode, I interview Jeremy Miller, Chairman and Founder of Healthy Commerce based in New York, United States. Jeremy has set up his own health consumer company to help people connect with their loved ones in the hospital or nursing home.  From working as an employee, Jeremy has decided to leave his former job to pursue bigger opportunities. Healthy Commerce was established in 2010 and has been running for over 12 years. Serving 60 million consumers with over 100 FTEs. Jeremy has said that growing a business requires building a good relationship with the people you work with within the industry to gain and maintain a good connection with your consumers. So he says, “Be the person that you need to be, meet people and build relationships.” This Cast Covers: 12 years in the industry of helping to grow a business. Allowing consumers to use pre-tax benefits such as FSA and HSA. Helping consumers to purchase 1000s and 1000s of eligible health care products and services Medicare. A core site that helps people by educating them on using tools that will help them spend money on qualified expenses. A growing company with over 100 core team members. Teaching entrepreneurs how to grow a business by building connections with other companies and employees. Helping entrepreneurs on how to bring their people. Enhancing patient care and improving a patient's experience. Teaching entrepreneurs how to use the right tools in growing a business. Additional Resources: Healthy Commerce, Inc. The Dealmaker's Ten Commandments by Jeff Cohen ___________________ Quotes: “Success is individual and personal, like an art, an attainment type of thing." —Jeremy Miller “You never know what's coming until it actually comes.” —Jeremy Miller“Be the person that you need to be, meet people and build relationships.” —Jeremy Miller “Learn to understand what's happening to avoid falling apart.” —Jeremy Miller “You need to know the place you want to be so that you can jump in the right direction.” —Jeremy Miller ___________________   Music from https://filmmusic.io “Cold Funk” by Kevin MacLeod https://incompetech.com. License: CC by http://creativecommons.org/licenses/by/4.0

In this episode, we are joined by Madison Robertson, a current research fellow and PhD Student in Health Quality here at Queen's University. Her current research seeks to understand the feelings of depression and loneliness for spouses who have been separated due to admission into long-term care. In this episode, we talk more about loneliness, the […]

In this episode, we get a look ahead, both at the future of NCQA's Quality Measurement agenda and our Quality Talks 2022 event.Dr. Eric Schneider is NCQA's recently-appointed Executive Vice President of the Quality Measurement and Research Group. In this role, he helps drive NCQA's efforts to create a more equitable health care system and to advance the move to digital quality measurement. Before that, he served as a Health Quality expert for both The Commonwealth Fund and the RAND Corporation. He taught public health policy at Harvard Medical and was a practicing primary care internist for over 25 years.But he was also co-Chair of NCQA's Committee on Performance Measurement for nearly 10 years, so he's no stranger to what we do here.Tosan Boyo is Senior Vice President for Hospital Operations at John Muir Health in the San Francisco Bay area. He also served as a leader of the San Francisco COVID-19 Operations Center, where they had the lowest case rates and highest testing rates of any high-density city in the country. Born in Nigeria and later raised in the U.S., Boyo backpacked around the world, gaining a global take on how Health Equity leads to improved Quality for all. Come see him speak, in person in Washington, DC, or online, at Quality Talks 2022.

Dr. Adam Wolfberg, MD, MPH, is the Chief Medical Officer at Current Health (https://currenthealth.com/), a Best Buy Health company (https://healthcare.bestbuy.com/) and part of the American multinational consumer electronics retailer. Current Health is an organization that enables the delivery of healthcare services in the home to enable healthcare organizations to deliver high-quality, patient-centric care at a lower cost. The company integrates patient-reported data with data from biosensors – including their own continuous monitoring wearable devices – to provide healthcare organizations with actionable, real-time insights into the patient's condition. Leveraging clinical algorithms that can be tailored to the individual patient, Current Health identifies when a patient needs clinical attention, allowing organizations to manage patient care remotely or coordinate in-home care via integrated service partners. The Current Health platform brings together tele-health capabilities, patient engagement tools, and in-home connectivity to provide a single solution to manage all care in the home. Dr. Wolfberg also leads implementation and account management at the organization. Previously, Dr Wolfberg worked in medical affairs at Ovia Health, a leading maternity and family benefits solution for employers and health plans (which was acquired by LabCorp), athenahealth (network-enabled services, mobile apps, and data-driven insights to hospitals and medical organizations) and Ariosa Diagnostics. Dr. Wolfberg trained in OB/GYN and maternal-fetal medicine at The Johns Hopkins University School of Medicine, and has an MPH from Johns Hopkins School of Hygiene and Public Health. Before going to medical school, Dr. Wolfberg was a print journalist. He blogs at www.adamwolfberg.com, and has written for magazines and websites including the Boston Globe Magazine, Slate.com, Huffington Post, and WSJ.com. His first book, Fragile Beginnings : Discoveries and Triumphs in the Newborn ICU, was published by Beacon Press in 2012.

We were joined by Kathleen Carberry, Assistant Professor at the Dell Medical School and Outcomes Program Officer at the Value Institute for Health and Care. She has been a registered nurse for 20 years and was the founder and director of the Texas Children's Hospital Outcomes & Impact Service that was dedicated to helping patients, families, and clinicians make better healthcare decisions using outcomes information. Our hosts for this episode, Steven Cutbirth (who is also Kathleen''s former student!) and Stephanie Pawlowski, discuss why measuring healthcare outcomes is so hard, the importance of value-based care, and why she is committed to improving the support system for caregivers.

In this episode, Ed interviews Chief Strategy Officer at Intelligent Medical Objects, Dale Sanders. They discuss the life journey Dale has taken to get where he is today and the changes that need to be made in public health quality measures. 

WHO: Sal Di Stefano---WHO IS THAT: Owner/founder of Mind Pump Media---TITLE/TOPICS: Why you should lift: Better health, quality of life, mobility, aesthetics, and confidence.---Where to find Sal:Instagram: @MindPumpSalPodcast: Mind PumpWebsite: Mindpumpmedia.com---Where to find me:Instagram: @JordanLipsFitnessEmail: JordanLips@Jordanlipsfitness.comPodcast: Where Optimal Meets PracticalWebsite: JordanLipsFitness.com---Apply for 1:1 Coaching HERESign up for FULL GYM group programming HERESign up for AT HOME group programming HERE---Helping you find the balance between OPTIMAL and PRACTICAL---Love You-JL

On Christmas Eve December 2020, the World Health Organisation named Antimicrobial Resistance (AMR) and health inequities as 2 of the 10 global health threats to track in 2021. In 2019, we worked with the Health Quality and Safety Commission (HQSC) and PHARMAC to see how we can tackle both in Aotearoa New Zealand. The results of this work have just been published in the New Zealand Medical Journal, so we wanted to dedicate this episode of Inside the Nudge Unit to it.  Peer-reviewed articles allow us to present the rigorous work that goes into running a Behavioural Insights (BI) project. However, journal articles often remove the work from its broader context and leave little space for describing the tribulations that go into running BI trials. In this episode, we cover the story of how the trial developed, and how it built on our earlier work in the UK and the work done by the Behavioural Economics Research Team in the Australian Department of Health (BERT) and the Behavioural Economics Team of the Australian government (BETA).  We discuss how health inequities in Aotearoa New Zealand meant that we couldn't just copy the letters used in the UK and Australia, and take a quick detour into the replication crisis. You'll hear from Michael Hallsworth, who led the work in the UK, Janice Wilson, the CEO of the HQSC, Rawiri Jansen, a GP and member of the project's working group, and Nathan Chapell, who developed the letters we used in the project.  Further reading If you would like to read more about health inequities in New Zealand, you can read the paper mentioned by Rawiri Jansen here, as well as its follow up here. You can also read about the follow up to the UK study here, and the follow up to the Australian study here.  If you are interested in learning more about the replication crisis, we would recommend this article. And if you would like to learn more about issues related to generalising studies from one area to another, we recommend you read this. Chapter 5 of Behavioral Insights, which was co authored by Michael Hallsworth (along with Elspeth Kirkman) also gives an overview of the issues discussed.  Thanks to the large team of people who were involved in the project, especially Janice Wilson, Catherine Gerard, Richard Hamblin, Carl Shuker, Janet Mackay, Rawiri McKree Jansen, Richard Medlicott, Aniva Lawrence, Sally Roberts, Jan White and Leanne Te Karu.  Music by Rich O'Brien https://open.spotify.com/playlist/1m3zn3SHmMh3vuR13hkLCP?si=e9e2193372664b6b Production by Alex Gyani.  Editing by Pixelife Studios. 

A new study has found selective "nudges" can help reduce the number of scripts for antibiotics being written by New Zealand GPs. Antibiotic resistance is a major threat to human health and on the rise around the world. Without action, the WHO says a post-antibiotic era could see common infections and minor injuries able to kill once again. New Zealand's Health Quality and Safety Commission and Pharmac teamed up with behavioural scientists to see whether targeting the top 30 percent of antibiotic-prescribing GPs would encourage change. To talk about the results, and the value of simple interventions to deal with issues around prescribing, Lynn Freeman is joined by Dr Alex Gyani, Director of Research and Methodology at Behavioural Insights Team, APAC.

A new study has found selective "nudges" can help reduce the number of scripts for antibiotics being written by New Zealand GPs. Antibiotic resistance is a major threat to human health and on the rise around the world. Without action, the WHO says a post-antibiotic era could see common infections and minor injuries able to kill once again. New Zealand's Health Quality and Safety Commission and Pharmac teamed up with behavioural scientists to see whether targeting the top 30 percent of antibiotic-prescribing GPs would encourage change. To talk about the results, and the value of simple interventions to deal with issues around prescribing, Lynn Freeman is joined by Dr Alex Gyani, Director of Research and Methodology at Behavioural Insights Team, APAC.

Today on the Take on Board podcast, Helga is speaking with Dr Monique Beedles about the boards role in asset management.Monique has been on a long list of Boards previously, Asset Management Council, Connexion Technology for Business, QUT Faculty of Creative Industries Faculty Academic Board and the Health Quality and Complaints Commission of QueenslandMonique is a Fellow of the Australian Institute of Company Directors and a graduate of their Company Directors Course and Chair's Course. Monique is a member of the AICD Faculty and facilitates their programs on Governance, Strategy and Risk.Monique's latest book, Asset Management for Directors was published by AICD in late 2016.Contact Monique or find out more about her:https://www.moniquebeedles.com/Resources mentioned in this episode:The Board's Role in Asset Management: https://mailchi.mp/moniquebeedles/boardsroleFOR MORE TAKE ON BOARD INFORMATION:Board Kickstarter: https://www.trybooking.com/BSJIB (EARLY BIRD PRICING UNTIL JULY 16)!Join the Take on Board community: https://www.facebook.com/groups/TakeOnBoard/Follow along on Twitter: @TakeOnBoardFor more information about Helga Svendsen: https://www.helgasvendsen.com.au/Interested in working with Helga? https://www.helgasvendsen.com.au/workwithmeContact Helga: helga@helgasvendsen.com.au

Living Health Quality with Dr. Johnson

Living Health Quality with Dr. Johnson

Living Health Quality with Dr. Johnson

Living Health Quality with Dr. Johnson

Living Health Quality with Dr. Johnson

Living Health Quality with Dr. Johnson

Living Health Quality with Dr. Johnson

Kendra Toothill       QUALITY TAKES PRECEDENCEKendra graduated from Concordia university in Montreal and has been a certified Athletic Therapist since 2013. She is also a certified Athletic Trainer in the US (ATC), a certified strength and conditioning coach CSCS and a certified yoga teacher. She's worked as an AT in both the UK and the US and has been an entrepreneur since opening up her first therapy clinic in Edmonton back in 2015.Kendra now works as a holistic women's health therapist and is the lead wellness program creator for corporate companies. She has studied research based fertility and ovulation methods and has created a system called Scars Reigniting Your Feminine System, for women who have scars and want to feel good again, trust their body and confidently take control of their health.  An outstanding discussion on living true. 

Living Health Quality with Dr. Johnson

Living Health Quality with Dr. Johnson

Glaring inequities for Maori hospitalised with life-threatening trauma have been unearthed by a new study. It's the first time the Health Quality and Safety Commission has examined whether critically injured Maori have the same survival rates as non-Maori. The findings are unequivocal - inequity exists. Tangata whenua are 56 percent more likely to die in the month after the trauma - excluding brain injuries - than non-Maori And Maori aged 15 - 18 are three times more likely to die. Dr Dick Ongley from the Commission told Meriana Johnsen questions need to be asked of DHBs.

Living Health Quality with Dr. Johnson and Dr. Sanderline

Living Health Quality with Dr. Johnson and Dr. Sanderline

During this 36-minute podcast, we talk to Heather O'Toole, M.D., chief medical officer at Innovation Care Partners, a clinically integrated network and an accountable care organization in Arizona.Dr. O'Toole, this year's recipient of RISE's Martin L. Block Award,  discusses the quality initiatives that have inspired her, including opioid safety in the ambulatory setting and training physicians on advance directives, as well as how the projects changed during COVID. 

Living Health Quality with Dr. Johnson

Living Health Quality with Dr. Johnson

Living Health Quality with Dr. Johnson

In this episode, Shakil Haroon, founder and CEO of MPIRICA, joins us to discuss why quality, affordable healthcare is hard to find (Hint: It was designed to be this way.) Shakil explains that hospitals have no interest in making quality data available because specialties with poor quality scores would lose revenue. With this in mind, Shakil created the MPIRICA Quality Score system to help patients find the best places to receive care.

Functional Nutritionists Stacy and Leah interview Ayurveda Practitioner Kyra Anastasia Sudofsky. What are the components of Ayurveda Medicine?Learn how awareness of your personal constitution can help you develop dietary and lifestyle behaviors to meet your individual needs, promote health and happiness. Stacy Seslowsky, RD, LDN, MS is now accepting new patients. Website: HealFromFood.com, Email: Stacy@HealFromFood.com, Social: @HealFromFood Leah Grace Barack, MS is now accepting new patients. Website: GraceFunctionalNutrition.com, Email: GraceFunctionalNutrition@gmail.com, Social: @GraceFunctionalNutrition Contact Kyra Anastasia Sudofsky, Ayurveda Practitioner via email: Ksudofsky@gmail.com